Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.38 |
| ▸ | OXTR | P30559 | 4/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.36 |
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
| ▸ | BRD2 | P25440 | 2/20 | 0.36 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4987515 | 0.89 | SMN1; SMN2 (0.40) | SMN1; SMN2KMT2AMEN1PABPC1OXTR | |
| SCHEMBL14186820 | 0.87 | OXTR (0.41) | SMN1; SMN2KMT2AMEN1GABRA5OXTR | |
| SCHEMBL4984447 | 0.86 | OXTR (0.41) | SMN1; SMN2KMT2AMEN1GABRA5OXTR | |
| SCHEMBL4990279 | 0.86 | AR (0.37) | SMN1; SMN2KMT2AMEN1GABRA5OXTR | |
| SCHEMBL4988506 | 0.85 | OXTR (0.40) | SMN1; SMN2KMT2AMEN1OXTRL3MBTL1 | |
| SCHEMBL4984496 | 0.84 | SMN1; SMN2 (0.40) | SMN1; SMN2KMT2AMEN1OXTRL3MBTL1 | |
| SCHEMBL4987284 | 0.83 | SMN1; SMN2 (0.45) | SMN1; SMN2KMT2AMEN1GABRA5OXTR | |
| SCHEMBL4982122 | 0.83 | SMN1; SMN2 (0.41) | SMN1; SMN2KMT2AMEN1OXTRL3MBTL1 | |
| SCHEMBL5783378 | 0.82 | LRRK2 (0.37) | GABRA5P2RX7 | |
| SCHEMBL4988267 | 0.81 | SMN1; SMN2 (0.40) | SMN1; SMN2KMT2AMEN1OXTRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080125409-A1 | 1,5-Diheterocycle-1H-Triazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-05-29 | — | — | US | disclosed |
| US-20080125409-A1 | 1,5-Diheterocycle-1H-Triazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-05-29 | — | — | US | disclosed |
| US-20080125409-A1 | 1,5-Diheterocycle-1H-Triazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-05-29 | — | — | US | disclosed |
| EP-1803719-A1 | 1,5-DIHETEROCYCLE-1H-TRIAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-07-04 | — | — | EP | disclosed |
| US-20060189591-A1 | Five-membered heterocyclic derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| EP-1621537-A1 | FIVE-MEMBERED HETEROCYCLIC DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125409-A1 | 1,5-Diheterocycle-1H-Triazole Derivative | PTGS1, PTGER1, TBXA2R | HTT 3347/4885SMN1; SMN2 3713/4885KMT2A 3245/4885 |
| US-20060189591-A1 | Five-membered heterocyclic derivative | PTGS1, PTGIS, PTGS2 | HTT 2548/4885SMN1; SMN2 3027/4885KMT2A 4143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.